Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study
The DOI matches its Crossref record, with a small difference in title or year.
Abstract
This double-blind placebo-controlled study specifically tested the efficacy of fluvoxamine, at a dose of 100 mg a day, in reducing the risk of new episodes of depression. Out of 436 patients treated openly with fluvoxamine 283 patients fulfilled stringent criteria to define responders at 6 weeks. A total of 204 patients maintained their remission throughout a continuation treatment period of 18 weeks and then entered the prophylactic study. They were randomly assigned to receive either fluvoxamine 100 mg a day or placebo for 1 year. There were significantly fewer recurrences of new episodes of depression in the fluvoxamine group compared with the placebo group (p < 0.001). The significant advantage for fluvoxamine was also seen in the Kaplan-Meier analysis of time to recurrence (p < 0.001). The clear-cut efficacy of 100 mg of fluvoxamine and the good tolerabilitv and side-effect profile demonstrated in this study support the view that fluvoxamine is particularly suitable for maintenance or prophylactic treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Participants in the discontinuation group (n = 94) had a higher endpoint score (5.8 (SD 3.0)) on the COVI Anxiety Scale than participants in the continuation group (n = 109) (4.7 (SD 2.4); P = 0.003), favouring continuation of long-term antidepressants.”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Terra 1998
In the citing paper
“Terra 1998 (n = 204) reported that two participants in the antidepressant group (n = 110) withdrew during the trial due to adverse events, along with zero participants in the discontinuation group (n = 94).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Terra 1998
In the citing paper
“Mean MADRS score was 12.5 (standard deviation (SD) 11.5) in the discontinuation group (n = 94) and 7.8 (SD 9.7) in the continuation group (n = 109).Study authors concluded that fluvoxamine continuation was more effective than discontinuation (P < 0.001).”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Terra 1998
Citations
Cites
Still being checked.
Cited by
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Maintenance Treatment of Major Depression in Old Age
Reynolds, C. F., Dew, M. A., Pollock, B. G., Mulsant, B. H., Frank, E., Miller, M. D., Houck, P. R., Mazumdar, S., Butters, M. A., Stack, J. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052619 · Cited by 476
Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression
Mace, S., & Taylor, D. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.5.917 · Cited by 315
Gartlehner, G., Gaynes, B. N., Hansen, R. A., Thieda, P., DeVeaugh-Geiss, A., Krebs, E. E., Moore, C. G., Morgan, L., & Lohr, K. N. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-10-200811180-00008 · Cited by 237
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
Metadata
- Authors
- Terra, J. L., & Montgomery, S. A.
- Affiliations
- Centre Hospitalier Le Vinatier (FR)
- Imperial College London (GB)
- ORCID
- Montgomery, S. A.
- Venue
- International Clinical Psychopharmacology
- Published
- 1998-03
- Volume
- 13
- Issue
- 2
- Pages
- 55-62
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W4300431066
- Semantic Scholar
- e289ccd24ec657c76658e012d053f66bba992e50
- Cited by
- 51
- References
- 0
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 2 · 2016: 1 · 2015: 3 · 2012: 2
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- fluvoxamine, depression recurrence, depression prevention, maintenance therapy, selective serotonin reuptake inhibitors, antidepressant efficacy, remission
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. https://app.cochat.ai/papers/10.1097/00004850-199803000-00001
- The paper
- Terra, J. L., & Montgomery, S. A. (1998). Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-199803000-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.